Investor Alert: Robbins LLP Informs Investors of the Skye Bioscience, Inc. Class Action
Robbins LLPinforms stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Skye Bioscience, Inc. (NYSE: FCX) securities between November 4, 2024 and October 3, 2025. Skye is a clinical stage biopharmaceutical company that focuses on developing molecules that modulate G protein-coupled receptors (“GPCRs”) to treat obesity, overweight, […]